96. クローン病 Crohn disease Clinical trials / Disease details


臨床試験数 : 2,442 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209

  
19 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-jRCT2031220309
01/11/202201/09/2022A Study of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn's DiseaseA Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn's Disease - DUET-CD Crohn's DiseaseGuselkumab
Guselkumab will be administered as subcutaneous injection.
Participants will receive guselkumab dose regimen 1 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.

Golimumab
Golimumab will be administered as subcutaneous injection.
Participants will receive golimumab dose regimen 1 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.

JNJ-78934804 (High-dose)
JNJ-78934804 will be administered subcutaneously as per defined regimen.
Participants will receive JNJ-78934804 dose regimen 1 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.

JNJ-78934804 (Mid-dose)
JNJ-78934804 will be administered subcutaneously as per defined regimen.
Participants will receive JNJ-78934804 dose regimen 2 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.

JNJ-78934804 (Low-dose)
JNJ-78934804 will be administered subcutaneously as per defined regimen.
Participants will receive JNJ-78934804 dose regimen 3 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Particip
Nishikawa KazukoNULLPending>= 18age old<= 65age oldBoth715Phase 2Argentina;Australia;Austria;Belgium;Bulgaria;Brazil;Canada;Switzerland;Chile;China;Czechia;Germany;Denmark;Spain;Estonia;France;United Kingdom Of Great Britain;Greece;Hungary;India;Israel;Italy;Korea;Republic Of Lithuania;Mexico;Netherlands;Norway;Poland;Portugal;Serbia;Japan
2JPRN-jRCT2031220205
22/08/202208/07/2022A Study of Guselkumab in Participants with Fistulizing, Perianal Crohn's DiseaseA Phase 3,Randomized,Placebo-controlled,Parallel-group,Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab in Participants with Fistulizing, Perianal Crohn's Disease - FUZION CD Fistulizing Crohns Disease Perianal Crohns DiseaseGuselkumab:Drug:Group 1: Guselkumab:Group 2: Guselkumab:Group 3: Placebo:Guselkumab will be administered subcutaneously/IV infusion.
Placebo:Drug:Group 1: Guselkumab:Group 2: Guselkumab:Group 3: Placebo:Matching placebo will be administered subcutaneously/IV infusion.
Numaguchi HirotakaNULLPending>= 18age oldNot applicableBoth280Phase 3Australia;Spain;Italy;Saudi Arabia;Belgium;France;Jordan;Sweden;Canada;United Kingdom Of Great Britain;Republic Of Korea;Turkey;Czechia;Greece;Netherlands;Taiwan;Germany;Hungary;Poland;United States Of America;Egypt;Israel;Portugal;Japan
3JPRN-jRCT2031210678
22/08/202218/03/2022A Study of Guselkumab Subcutaneous Therapy in Participants with Moderately to Severely Active Crohn's DiseaseA Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants With Moderately to Severely Active Crohn's Disease - GRAVITI Crohn DiseaseGuselkumab Dose 1:Drug:Group 1: Guselkumab,Group 2: Guselkumab:Guselkumab (Dose 1) will be administered by subcutaneous (SC) injection.
Guselkumab Dose 2:Drug:Group 1: Guselkumab:Guselkumab (Dose 2) will be administered by SC injection.
Guselkumab Dose 3:Drug:Group 2: Guselkumab:Guselkumab (Dose 3) will be administered by SC injection.
Placebo:Drug:Group 3: Placebo:Placebo will be administered by SC injection.
Hirotaka NumaguchiNULLPending>= 18age oldNot applicableBoth318Phase 3Australia;Belarus;Belgium;Bosnia And Herzegovina;Brazil;Canada;China;Croatia;Czechia;Germany;Hungary;Italy;Jordan;Korea;France;Lithuania;Netherlands;NewZealand;Poland;RussianFederation;Serbia;Slovakia;Spain;Taiwan,Province Of China;Turkey;Ukraine;United Kingdom Of Great Britain;UnitedStates Of America;Japan
4JPRN-jRCT2031220186
10/08/202206/07/2022A Basket Long-term Extension Study of Ustekinumab in Pediatric ParticipantsA Phase 3, Multicenter, Open-label, Basket, Long-term Extension Study of Ustekinumab in Pediatric Clinical Study Participants (2 to <18 Years of Age) Crohn Disease, Ulcerative Colitis, Psoriatic ArthritisParticipants will have continued access to ustekinumab for primary study (CNTO1275CRD1001, CNTO1275PUC3001, CNTO1275CRD3004 & CNTO1275JPA3001) participants who in the opinion of the investigator will continue to benefit from ustekinumab therapy. All blinded participants who enroll in the long-term extension (LTE) from blinded primary studies with both every 8 weeks (q8w) and every 12 weeks (q12w) dosing groups just prior to the end of the primary study will be assigned to the q8w dosing regimen. Participants enrolling in the LTE from an unblinded primary study will remain on the final dosing regimen that they were receiving in the primary study. Ustekinumab will be administered as a SC injection.Nishikawa KazukoNULLPending>= 2age old< 18age oldBoth151Phase 3France;Poland;United States Of America;Japan
5ChiCTR2200058343
2022-04-132022-04-07To investigate the effect of pancreatin on diarrhea of crohn's disease patients taking total enteral nutritionTo investigate the effect of pancreatin on diarrhea of crohn's disease patients taking total enteral nutrition Crohn's diseaseExperimental group:Take trypsin medications;Renmin Hospital of Wuhan UniversityNULLPending1875BothExperimental group:53;Phase 4China
6ChiCTR2200058055
2022-04-012022-03-27A prospective, multicenter observational study of adalimumab biological analogues combined with partial enteral nutrition in the evaluation of the efficacy of Crohn's diseaseA prospective, multicenter observational study of adalimumab biological analogues combined with partial enteral nutrition in the evaluation of the efficacy of Crohn's disease Inflammatory bowel disease (IBD)Hemienteral nutrition group:adalimumab biological analogues combined with partial enteral nutrition therapy;Internal nutrition group:adalimumab combined with total enteral nutrition;The adamumab group:adalimumab;The First Affiliated Hospital of Shantou University Medical CollegeNULLPending1875BothHemienteral nutrition group:30;Internal nutrition group:30;The adamumab group:60;N/AChina
7JPRN-jRCT2031210677
18/03/202218/03/2022A study to test whether spesolimab helps people with Crohn's disease who have symptoms of bowel obstructionMulti-center, double-blind, randomized, placebo-controlled, phase IIa trial to evaluate spesolimab (BI 655130) efficacy in patients with fibrostenotic Crohn's Disease fibrostenotic Crohn's DiseaseInvestigational Drug: Spesolimab, Placebo
Dose: 1200 mg spesolimab or placebo every 4 weeks (Day 1 to Week 8), then 1200 mg spesolimab or placebo every 8 weeks until Week 40
Mode of Administration: intervenous
Taguchi AyaNULLPending>= 18age old<= 75age oldBoth3Phase 2Australia;Austria;Belgium;Brazil;Canada;China;Denmark;France;Germany;Ireland;Israel;Italy;Republic of Korea;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Serbia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;Japan
8ChiCTR2100048717
2021-07-012021-07-13Clinical trial of the efficacy and safety of dipyridamole adjuvant therapy in children with IBDClinical trial of the efficacy and safety of dipyridamole adjuvant therapy in children with IBD Crohn's diseaseTwo groups:Oral dipyridamole;Guangzhou Women and Children's Medical CenterNULLPending318BothTwo groups:50;China
9JPRN-UMIN000043165
2021/02/0131/01/2021Safety and efficacy of non-medical switching from originator infliximab to infliximab biosimilar CT-P13 in patients with inflammatory bowel diseaseSafety and efficacy of non-medical switching from originator infliximab to infliximab biosimilar CT-P13 in patients with inflammatory bowel disease - Safety and efficacy of non-medical switching from originator infliximab to infliximab biosimilar CT-P13 in patients with inflammatory bowel disease Crohn's disease, Ulcerative colitis, IBDUwitching from originator infliximab to infliximab biosimilar CT-P13Fukuoka University Chikushi HospitalNULLPendingNot applicableNot applicableMale and Female220Not selectedJapan
10ChiCTR2000036845
2021-01-012020-08-25A single-center, randomized, controlled study on the effect of proactive therapeutic drug monitoring on the efficacy and cost of adamumab in the treatment of Crohn's diseaseA single-center, randomized, controlled study on the effect of proactive therapeutic drug monitoring on the efficacy and cost of adamumab in the treatment of Crohn's disease Crohn's diseaseProctive treatment drug monitoring group:In the proactive TDM group, adamumab is 160mg at week 0, 80mg at week 2, and 40mg once every two weeks from week 4 until week 8. Adalimumab serum trough concentration is going to be monitored at week 8, 16, 24, 32 and 40 after inclusion: 1.If serum trough concentration=11.7 g/ mL, continue&#;Reactive treatment drug monitoring group:In the reactive TDM group, adamumab is 160mg at week 0, 80mg at week 2, and 40mg once every two weeks from week 4 until week 8. Clinical response is assesed at week 8, 16, 24, 32, and 40 after inclusion: 1.If the clinical response is achieved, continue to administer 40mg once every ;Xinhua Hospital Affiliated to Shanghai Jiaotong University School of MedicineNULLPending1870BothProctive treatment drug monitoring group:60;Reactive treatment drug monitoring group:60;Phase 4China
11ChiCTR2000035737
2020-10-012020-08-16Application of indocyanine green fluorescence angiography in preventing anastomotic recurrence after Crohn’s disease intestinal resection and anastomosis: a single-center, prospective, randomized controlled trialApplication of indocyanine green fluorescence angiography in preventing anastomotic recurrence after Crohn’s disease intestinal resection and anastomosis: a single-center, prospective, randomized controlled trial Crohn's diseaseExperimental group:The scope of surgical resection was determined by indocyanine green fluorescence angiography;Control group:The scope of surgical resection (2cm away from the lesion site) determined by the physician based on experience;Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of MedicineNULLPending1870BothExperimental group:45;Control group:45;China
12ChiCTR2000031344
2020-05-012020-03-28Endoscopic Stricturotomy combined with local injection of bleomycin in the treatment of primary anorectal stricture in crohn's disease: a Prospective, double-blind, randomized controlled clinical studyEndoscopic Stricturotomy combined with local injection of bleomycin in the treatment of primary anorectal stricture in crohn's disease: a Prospective, double-blind, randomized controlled clinical study Crohn's diseaseGroup 1:Endoscopic Stricturotomy;Group 2:Endoscopic Stricturotomy combined with local bleomycin injection;The Ninth People's Hospital Affiliated to Shanghai Jiaotong University School of MedicineNULLPendingBothGroup 1:35;Group 2:35;China
13ChiCTR2000029323
2020-03-012020-01-25Laparoscopic bowel resection combined with infliximab treatment versus infliximab for localized intestinal Crohn's disease: a randomized controlled, open-label trialLaparoscopic bowel resection combined with infliximab treatment versus infliximab for localized intestinal Crohn's disease: a randomized controlled, open-label trial Crohn's diseaseExperimental group:Laparoscopic bowel resection combined with postoperative Infliximab treatment;Control group:Infliximab;Renji Hospital, School of Medicine, Shanghai Jiaotong UniversityNULLPending1880BothExperimental group:30;Control group:30;China
14ChiCTR1900026091
2019-09-192019-09-20Development of a predictive nomogram for primary non-response to infliximab in patients with Crhon's diseaseDevelopment of a predictive nomogram for primary non-response to infliximab in patients with Crhon's disease: a multicenter study Crohn's diseaseCase series:infliximab;The First Affiliated Hospital of Sun Yat-sen UniversityNULLPending958BothCase series:343;China
15ChiCTR1900023696
2019-07-012019-06-08Endoscopic balloon dilatation combined with local betamethasone injection to prevent recurrence of anastomotic stenosis after ileocolic resection for Crohn's disease: a single-center prospective randomized controlled trialEndoscopic balloon dilatation combined with local betamethasone injection to prevent recurrence of anastomotic stenosis after ileocolic resection for Crohn's disease: a single-center prospective randomized controlled trial Chron's diseaseGroup 1:EBD;Group 2:EBD combined with local injection of betamethasone;The Sixth Affiliated Hospital of Sun Yat-sen UniversityNULLPending1875BothGroup 1:45;Group 2:45;N/AChina
16JPRN-JapicCTI-194830
01/7/201927/06/2019Specified Drug-Use Survey on Vedolizumab for IV Infusion 300 mg [Crohn's Disease]Specified Drug-Use Survey on Entyvio for IV Infusion 300 mg [Crohn's Disease] Crohn's diseaseIntervention name : Vedolizumab (Genetical Recombination)
INN of the intervention : Vedolizumab
Dosage And administration of the intervention : Vedolizumab (Genetical Recombination) 300 milligrams (mg), intravenous (IV) infusion, at Weeks 0, 2 and 6, and every 8 weeks thereafter, for up to 54 weeks. Participants will receive IV infusion as part of routine medical care.
Control intervention name : -
INN of the control intervention : -
Dosage And administration of the control intervention : -
Takeda Pharmaceutical Company LimitedNULLpendingBOTH300NAJapan
17ChiCTR1900022728
2019-05-012019-04-23Cohort study combined with omics screening for the early diagnostic markers in Crohn's diseaseCohort study combined with omics screening for the early diagnostic markers in Crohn's disease Crohn's diseaseGold Standard:Clinical outcome;Index test:Comprehensive serological markers, metabolomics, intestinal microbes, pathological features, imaging features of clinical subclinical CD, combined with clinical and endoscopic features, to explore early diagnosis of CD;The 7th Medical Center of the PLA General Hospital (Army general hospital)NULLPendingBothTarget condition:310;Difficult condition:160China
18EUCTR2018-003303-19-PL
(EUCTR)
15/03/201923/01/2019A Phase II Study in Patients With Moderate to Severe Active Crohn’s Disease.A Phase II randomized, placebo controlled, double-blind, 4 arms dose-ranging study to evaluate the efficacy and safety of SHR0302 compared to placebo in patients with moderate to severe active Crohn’s Disease. Crohn’s Disease
MedDRA version: 20.0;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Code: SHR0302
INN or Proposed INN: Pending
Reistone Biopharma Company LimitedNULLNot RecruitingFemale: yes
Male: yes
144Phase 2United States;Poland;Ukraine;China
19ChiCTR1800015174
2018-05-012018-03-12Effects of Vitamin D supplementation on clinical prognosis for patients with Crohn's diseaseEffects of Vitamin D supplementation on clinical prognosis for patients with Crohn's disease Crohn's diseasecontrol group:placebo;Vitamin D:800IU Vitamin D;Gudangdong General Hospital, Guangdong Academy of Medical SciencesNULLPending1875Bothcontrol group:32;Vitamin D:32;China